CorMedix (CRMD)
(Delayed Data from NSDQ)
$5.26 USD
-0.03 (-0.47%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $5.25 -0.01 (-0.10%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.26 USD
-0.03 (-0.47%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $5.25 -0.01 (-0.10%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Zacks News
CorMedix (CRMD) Upgraded to Buy: Here's Why
by Zacks Equity Research
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Momentum Investors Will Love CorMedix (CRMD)
by Zacks Equity Research
Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 15.38% and 116.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Jumps: Stock Rises 9.8%
by Zacks Equity Research
CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
CorMedix (CRMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 41.67% and -83.16%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Jumps: Stock Rises 7.5%
by Zacks Equity Research
CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
CorMedix (CRMD) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CorMedix (CRMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Momentum Stocks to Buy for April 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 22nd
Will CorMedix Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor CorMedix
Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%
by Zacks Equity Research
Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
CorMedix (CRMD) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 12.50% and -73.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CorMedix (CRMD) Q4 Earnings Expected to Decline
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 12.00% and -68.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of -9.09% and -73.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 24.14% and 173.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in CorMedix (CRMD) Stock
by Zacks Equity Research
Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.
Implied Volatility Surging for CorMedix (CRMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Sectors of July & Their Top Stocks
by Sanghamitra Saha
Inside the top sectors of July and their top-performing stocks.
Are Options Traders Betting on a Big Move in CorMedix (CRMD) Stock?
by Zacks Equity Research
Investors in CorMedix (CRMD) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in CorMedix (CRMD) Stock?
by Zacks Equity Research
Investors in CorMedix (CRMD) need to pay close attention to the stock based on moves in the options market lately.